Taysha Gene Therapies (TSHA) Total Debt (2020 - 2026)

Taysha Gene Therapies has disclosed Total Debt across 7 years of filings, most recently posting $49.0 million for Q1 2026.

• Total Debt for Q1 2026 came in at $49.0 million, up 15.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.0 million (up 15.33% YoY), and the FY2025 annual result was $50.1 million, up 14.03% from the prior year.
• Total Debt came in at $49.0 million for Q1 2026 at Taysha Gene Therapies, down from $50.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $179.1 million in Q3 2023 to a low of $37.4 million in Q1 2022.
• The 5-year median for Total Debt is $40.5 million (2024), against an average of $49.7 million.
• Across the five-year window, Total Debt surged 374.1% in 2023 and sank 76.0% in 2024, its largest moves.
• Taysha Gene Therapies' Total Debt stood at $38.0 million in 2022, then increased by 6.69% to $40.5 million in 2023, then increased by 8.48% to $43.9 million in 2024, then gained by 14.03% to $50.1 million in 2025, then retreated by 2.29% to $49.0 million in 2026.
• The last three Total Debt figures came in at $49.0 million (Q1 2026), $50.1 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.